Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Current Deferred Revenue (2016 - 2025)

OptimizeRx's Current Deferred Revenue history spans 16 years, with the latest figure at $395000.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 49.75% year-over-year to $395000.0; the TTM value through Sep 2025 reached $395000.0, down 49.75%, while the annual FY2024 figure was $4.3 million, 2393.02% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $395000.0 at OptimizeRx, down from $484000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $4.3 million in Q4 2024 and bottomed at $164000.0 in Q4 2022.
  • The 5-year median for Current Deferred Revenue is $511000.0 (2025), against an average of $823433.6.
  • The largest annual shift saw Current Deferred Revenue plummeted 88.2% in 2022 before it soared 2393.02% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.4 million in 2021, then tumbled by 88.2% to $164000.0 in 2022, then grew by 4.88% to $172000.0 in 2023, then skyrocketed by 2393.02% to $4.3 million in 2024, then plummeted by 90.79% to $395000.0 in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Current Deferred Revenue are $395000.0 (Q3 2025), $484000.0 (Q2 2025), and $511000.0 (Q1 2025).